OXFORD, UK AND CAMBRIDGE, Massachusetts – June 8, 2026
Moderna and the University of Oxford have received authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to begin a Phase 1/2 clinical study evaluating mRNA-4194, an investigational mRNA-based cancer vaccine designed for people with Lynch syndrome. The milestone marks a significant advance in the emerging field of cancer prevention through mRNA technology and represents Moderna’s first investigational program focused specifically on preventing cancer before it develops. The trial, known as INTERCEPT-Lynch, aims to determine whether the vaccine can stimulate immune responses against biological targets associated with the earliest stages of cancer formation in individuals at exceptionally high genetic risk. The authorization highlights growing interest in applying mRNA technology beyond infectious diseases and therapeutic oncology into preventive medicine, opening a potential new frontier in cancer care.
Investigational mRNA Vaccine Targets Hereditary Cancer Risk
Lynch syndrome is the most common inherited cancer predisposition condition, affecting approximately one in every 300 people worldwide and increasing lifetime cancer risk by as much as 80%. The genetic disorder results from mutations in DNA repair genes, allowing genetic errors to accumulate and increasing the likelihood of developing colorectal, endometrial, ovarian, stomach, prostate, and several other cancers. Current management strategies largely rely on intensive surveillance, preventive surgery in selected cases, and limited pharmacological interventions.
Moderna’s investigational mRNA-4194 vaccine is designed to train the immune system to recognize and respond to molecular changes associated with early cancer development, often referred to as “pre-cancer.” By targeting these biological signals before tumors emerge, researchers hope to reduce cancer incidence among individuals carrying Lynch syndrome-associated mutations. The study will initially assess safety, immune responses, and dose optimization before expanding to additional participants and clinical centers throughout the United Kingdom. The first patient is expected to receive the vaccine during the summer of 2026, while the second phase of the study is planned for 2027.
Oxford and Moderna Advance Precision Cancer Prevention
Advertisement
The INTERCEPT-Lynch study forms part of a broader scientific collaboration between Moderna and the University of Oxford, bringing together expertise in genomics, immunology, oncology, and mRNA technology. Sponsored by the University of Oxford and funded by Moderna, the trial will be conducted through Oxford’s Oncology Clinical Trials Office and Oxford Cancer Centre. Researchers believe that preventing cancer development in genetically high-risk populations may ultimately reduce the need for aggressive treatments and improve long-term patient outcomes. According to investigators, the study represents an important example of precision prevention, an emerging research strategy that identifies high-risk populations and deploys biologically targeted interventions before disease develops.
By combining advanced genomic insights with Moderna’s mRNA platform, the collaboration aims to establish whether immune-based preventive approaches can transform the management of hereditary cancer syndromes. The project also reinforces Oxford’s expanding precision cancer prevention program, which seeks to develop innovative interventions tailored to specific genetic and biological risk profiles.
Strengthening the Future of mRNA-Based Cancer Prevention
The new study also reflects the strength of Moderna’s long-term commitment to the United Kingdom through its strategic partnership with the UK Government. Established in 2022, the partnership has supported the expansion of mRNA research infrastructure, including the Moderna Innovation and Technology Centre in Oxfordshire and numerous UK-based clinical studies. For Moderna, mRNA-4194 represents a potentially transformative step toward shifting cancer care from treatment to prevention, leveraging immune system activation at the earliest stages of disease development.
If successful, the program could establish a new model for preventing hereditary cancers and pave the way for future preventive vaccines targeting other high-risk populations. As global interest in precision medicine, immunotherapy, and cancer prevention continues to grow, the INTERCEPT-Lynch trial could become one of the most closely watched clinical programs exploring the next generation of mRNA-based healthcare innovations.
Source: Moderna press release
